Edition:
United States

Ophthotech Corp (OPHT.OQ)

OPHT.OQ on NASDAQ Stock Exchange Global Select Market

2.61USD
11:34am EST
Change (% chg)

$-0.04 (-1.51%)
Prev Close
$2.65
Open
$2.68
Day's High
$2.68
Day's Low
$2.58
Volume
20,735
Avg. Vol
140,501
52-wk High
$4.60
52-wk Low
$2.24

Latest Key Developments (Source: Significant Developments)

Ophthotech Q3 earnings per share $5.25
Wednesday, 8 Nov 2017 07:00am EST 

Nov 8 (Reuters) - Ophthotech Corp ::Ophthotech reports third quarter 2017 financial and operating results.Q3 earnings per share $5.25.Q3 earnings per share view $2.67 -- Thomson Reuters I/B/E/S.Ophthotech Corp - ‍collaboration revenue was $206.7 million for quarter ended September 30, 2017, compared to $1.7 million for same period in 2016​.Ophthotech Corp - ‍as of September 30, 2017, company had $180.2 million in cash and cash equivalents​.Ophthotech Corp - ‍expects a 2017 year end cash balance of between $155 million and $165 million​.  Full Article

Ophthotech announces results from phase 3 trial of Fovista
Monday, 14 Aug 2017 06:30am EDT 

Aug 14 (Reuters) - Ophthotech Corp ::Ophthotech announces results from third phase 3 trial of Fovista® in wet age-related macular degeneration.Ophthotech corp - ‍pre-specified primary endpoint of mean change in visual acuity at 12 months was not achieved​.Ophthotech - ‍did not observe any clinically meaningful visual benefit in pre-specified secondary endpoints when fovista was added to eylea or avastin regimen​.Ophthotech - ‍addition of 1.5mg of Fovista to Eylea or avastinregimen did not result in benefit as per mean change in visual acuity at 12-month point​.Ophthotech - ‍ocular adverse events more frequently reported in fovista combination therapy group compared to eylea or avastin monotherapy group were mainly related to injection procedure​.Says ‍company has decided to stop treating patients who are in second year of oph1004 study​.Ophthotech - ‍based on a preliminary analysis, fovista combination therapy & eylea or avastin monotherapy were generally well tolerated after 1 year.  Full Article

Ophthotech reports second quarter 2017 financial and operating results
Wednesday, 26 Jul 2017 06:33am EDT 

July 26 (Reuters) - Ophthotech Corp :Q2 loss per share $0.62.Q2 earnings per share view $1.05 -- Thomson Reuters I/B/E/S.Ophthotech Corp says initial, top-line data from company's Fovista OPH1004 trial, its remaining Phase 3 clinical trial, are expected in Q3 of 2017.Ophthotech Corp - collaboration revenue was $1.7 million for quarter ended June 30, 2017, compared to $28.2 million for same period in 2016.Ophthotech Corp - expects a 2017 year end cash balance of between $145 million and $160 million.Ophthotech - failure of two previous phase 3 Fovista clinical trials, failure of competitor's Phase 2 clinical trial indicative of low likelihood of success for OPH1004.  Full Article

Ophthotech and Novartis Pharma enters into a letter agreement with respect to licensing and commercialization agreement
Monday, 10 Jul 2017 07:59am EDT 

July 10 (Reuters) - Novartis AG ::Ophthotech - on July 3, co and Novartis Pharma entered into a letter agreement with respect to licensing and commercialization agreement dated May 19, 2014.Ophthotech - under 2014 agreement, co had granted novartis exclusive rights to develop and commercialize fovista products in all countries outside of U.S..Ophthotech - pursuant to July 3 letter agreement, parties agreed to suspend their affirmative obligations under 2014 agreement regarding fovista products.Ophthotech - agreement to suspend affirmative obligations regarding fovista products is pending receipt of oph1004 data and determination of a regulatory strategy.Ophthotech - letter agreement also provides Novartis with a shorter notice period in the event Novartis determines to terminate the 2014 agreement in certain circumstances.  Full Article

David Shaw reports a 5 pct passive stake in Ophthotech Corp as of May 11, 2017
Monday, 22 May 2017 04:02pm EDT 

May 22 (Reuters) - Ophthotech Corp :David Shaw reports a 5.0 percent passive stake in Ophthotech Corp as of May 11, 2017 - SEC filing.  Full Article

Ophthotech reports Q1 loss per share $1.20
Wednesday, 3 May 2017 07:30am EDT 

May 3 (Reuters) - Ophthotech Corp -:Ophthotech reports first quarter 2017 financial and operating results.Q1 loss per share $1.20.Q1 earnings per share view $-1.32 -- Thomson Reuters I/B/E/S.Ophthotech Corp - collaboration revenue was $1.7 million for quarter ended march 31, 2017, compared to $15.7 million for same period in 2016.  Full Article

Ophthotech says Glenn Sblendorio to become chief executive officer
Monday, 24 Apr 2017 04:15pm EDT 

April 24 (Reuters) - Ophthotech Corp :Says Glenn Sblendorio to become chief executive officer.Says David Carroll promoted to chief financial officer, effective immediately.Says David Guyer to transition to executive chairman.Ophthotech Corp says Sblendorio's appointment as CEO effective July 1, 2017.  Full Article

Ophthotech reports Q4 loss per share $1.86
Tuesday, 28 Feb 2017 07:00am EST 

Ophthotech Corp : Ophthotech reports fourth quarter and full year 2016 financial and operating results . Q4 loss per share $1.86 . Q4 earnings per share view $-1.69 -- Thomson Reuters I/B/E/S .Qtrly collaboration revenue $ 5.3 million $ 4.9 million.  Full Article

Ophthotech names Keith Westby COO
Wednesday, 1 Feb 2017 06:30am EST 

Ophthotech Corp : Ophthotech announces strategic review plan . Ophthotech Corp says Glenn P. Sblendorio assumes position of president and Keith Westby takes on role of chief operating officer . Sblendorio also will continue to serve as chief financial officer . Ophthotech Corp says it is to actively explore obtaining rights to additional products, product candidates and technologies to treat ophthalmic diseases .Ophthotech says has engaged Leerink Partners Llc as its financial advisor to assist management and board in evaluating company's strategic alternatives.  Full Article

Ophthotech Q3 loss per share $1.71
Tuesday, 8 Nov 2016 07:30am EST 

Ophthotech Corp : Collaboration revenue was $1.7 million for quarter ended September 30, 2016, compared to $3.4 million for prior year period. . Ophthotech reports third quarter 2016 financial and operating results . Q3 loss per share $1.71 .Q3 earnings per share view $-1.64 -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-Ophthotech Q3 earnings per share $5.25

* Ophthotech reports third quarter 2017 financial and operating results